Internal Medicine, Infectious...
Transcript of Internal Medicine, Infectious...
![Page 1: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/1.jpg)
Ernesto Martínez B., MDInternal Medicine, Infectious Diseases
![Page 2: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/2.jpg)
Disclosure – C.O.I.
1. Honorary as speakers from MSD, ViiV, GSK, Gilead, Stendhal, Janssen and Abbvie
2. Honorary in Advisory Boards from MSD, ViiV/GSK, Gilead and Stendhal
3. Research Grants from ViiV/GSK.
4. Financial Support for medical Education foundations and networking fromGSK, MSD, Stendhal, Abbvie and Janssen
![Page 3: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/3.jpg)
• Cognitive complaints common in HIV:
o Acute delirium secondary to metabolic and infectious complications
o Other chronic cognitive impairments not directly related to HIV (alcohol and/or other drugs, Hep C, vascular, seizures)
o Cognitive symptoms associated psychiatric illness
o HAND: HIV-associated neurocognitive disorders is the virus
![Page 4: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/4.jpg)
• Casos: 2854; Controles: 8562• Co-morbilidades evaluadas: Hipertensión, DM, ECV y osteoporosis.• La prevalencia de comorbilidades fué MAYOR en los VIH+ que en VIH neg. en todas las edades
(todos p <0.001)• La prevalencia de poli-Patología en HIV+ fue similar a la observada en la población general pero
10 años más tarde!Guaraldi G et al. Clin Infect Dis 2011; 53: 1120-1126
![Page 5: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/5.jpg)
Direct relation between clinical stage and presence of HAND,but more asymptomatic patients have ANI in CART era
(1). Heaton RK., et al. J. Neurovirol. (2011) 17:3–16(2). Bhaskaran K., et al. Ann Neurol 2008;63:213–221
***p=0.001
(1)
(2)
![Page 6: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/6.jpg)
HIV infection without cognitive
impairment
HIV Asymptomatic Neurocognitive
Impairment
Mild Neurocognitive
Disorder
HIV-associated Dementia
Consensus Working Group, Neurology 2007
![Page 7: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/7.jpg)
Neuropsychological Testing
Function
Asymptomatic Neurocognitive Impairment (ANI)
Any degree of impairmentin at least two cognitive domains
No identifiedimpairment
Mild Neurocognitive Disorder (MND)
Mild-moderately impaired in at least two cognitive domains
Typically mild to moderate impairment
HIV-associated Dementia (HAD)
More severely impaired in at least two cognitive domains
Typically more severeimpairment
Antinori A., et al. Neurology. 2007 30; 69(18): 1789–1799
All “HIV encephalopathy”
![Page 8: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/8.jpg)
(1). Grant I. International Review of Psychiatry 2008;20(1):33-47.(2). Clifford DB. Top HIV Med 2008 Jun-Jul;16(2):94-8
(3). McArthur, J. C. et al. Ann. Neurol. 67, 699–714 (2010)
(1)(2)
(3)
• 15–55% of HIV+ individuals are estimated to have HAND
• Conclusion: Prevalence is the same,• Distribution of diagnosis and severity
have changed with HAART
• Grant Pre-HAART (≈ 50%)• CHARTER (CNS HIV Antiretroviral Therapy
Effects Research) HAART era (≈ 55%)
![Page 9: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/9.jpg)
Neurocognitive impairment rate is higher in older compared to youngerindividuals.
CROI, Seattle, February 13-16, 2017. Abstract 343.
![Page 10: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/10.jpg)
• Nearly 100% adherent – can’t compare to younger cohorts• More symptomatic impairment• Survival tendencies
From VG Valcour, MD, at Atlanta, GA: April 10, 2013, IAS-USA.
![Page 11: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/11.jpg)
• Older than 50 yo.• Female gender• More advanced HIV disease (including CD4 count of <100
cells/µL, wasting)• Time living with HIV• High plasma HIV RNA (viral load)• Comorbid conditions (anemia, metabolic dis., infection with
cytomegalovirus, human herpesvirus 6, HCV, and JC virus)• History of injection drug use (especially with cocaine)• History of delirium• Host genetic factors: Polymorphisms (Apo E4, CCR2, MCP-1)
Modified from https://aidsetc.org/guide/hiv-associated-neurocognitive-disorders
![Page 12: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/12.jpg)
Williams, D. W. et al. Curr. HIV Res. 12, 85–96 (2014)
![Page 13: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/13.jpg)
• MMSE (not very sensitive, Crum et al., 1993)• HIV Dementia Scale (Power et al., 1995)• International HIV Dementia Scale (Sacktor et al.,
2005)• Montreal Cognitive Assessment (MoCA, Overton et
al. CROI 2011)• MOS-IV
![Page 14: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/14.jpg)
![Page 15: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/15.jpg)
Antinori A., et al. Neurology. 2007 30; 69(18): 1789–1799
• Of 37 patients who at baseline were neurocognitively normal, at 1 year 30% had progressed to some stage of impairment.
• Of 53 patients initially diagnosed with asymptomatic NP, 17.7% were classified as normal 1 year later, while 44.1% had progressed to more severe categories of impairment.
Diagnostic transitions from baseline to year 1
![Page 16: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/16.jpg)
Cysique LA., et al. Neurology. 2009 Aug 4;73(5):342-8.
Clinically meaningful neuropsychological improvement seemed to peak around24–36 weeks after cART initiation and was prolonged over the 1-year study period.
37 HIV+ individuals with mild to moderate NP impairmentwho initiated CART
![Page 17: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/17.jpg)
The Mind Exchange Working Group. Clinical Infectious Diseases 2013;56(7):1004–1
![Page 18: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/18.jpg)
Letendre S.Top Antivir Med. 2011 Nov;19(4):137-42.
![Page 19: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/19.jpg)
* Agents included in recommended regimens for initial therapy.¶ Agents that are not used in regimens for initial therapy.Δ Agents included in alternative regimens for initial therapy.◊ Agents included in other regimens for initial therapy.
Adapted from: Letendre S. Top Antivir Med 2011; 19:137.
![Page 20: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/20.jpg)
Letendre S.Top Antivir Med. 2011 Nov;19(4):137-42.
![Page 21: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/21.jpg)
Higher CPE scores correlated with greater improvements in NPZ-4 (P = 0.0283), NPZ-8 (P = 0.0071), concentration and speed of mental processing (P = 0.0046), and mental flexibility (P = 0.0262) summary z scores. The correlation was stronger among NP-impaired patients.
Tozzi V., et al. J Acquir Immune Defic Syndr 2009;52:56–63
![Page 22: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/22.jpg)
Rates of new CNS event (A) stratified by initial and most recent central nervous penetration effectiveness (CPE) scores (B)
Garvey L., et al. Neurology 2011;76:693–700
• CNS diseases (HIVenc, PML, Toxo, Crypto) occurred more frequently using cARTwith CPE scores ≤4, and less frequently with scores ≥10; the differences were nonsignificant.
• Initial and most recent cART CPE scores ≤4 were independently associated with increased risk of death
![Page 23: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/23.jpg)
Heaton RK., ET AL. Neurology. 2010;75:2087–2096
54.2%
15.4%
30.4%N = 1555 HIV+ indiv.
Observational, cross-sectional
71% on cART
Prevalence:33% ANI
12% MND2% HAD
![Page 24: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/24.jpg)
Caniglia EC., et al. Neurology. 2014;83:134–141
![Page 25: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/25.jpg)
Estimated log hazard ratios and 95% confidence intervals
Caniglia EC., et al. Neurology. 2014;83:134–141
Number initiating treatment by CPE score
Most frequently used cART regimens with a low, medium, and high CPEscore, HIV-CAUSAL Collaboration, 1998–2013
![Page 26: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/26.jpg)
* Agents included in recommended regimens for initial therapy.¶ Agents that are not used in regimens for initial therapy.Δ Agents included in alternative regimens for initial therapy.◊ Agents included in other regimens for initial therapy.
Adapted from: Letendre S. Top Antivir Med 2011; 19:137.
![Page 27: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/27.jpg)
• Prospective, double observer-blinded, open-label pilot randomized-controlled trial. Participants were randomized to remain on their existing cART régimen (control arm; n = 8) or receive maraviroc-intensification (maraviroc arm; n = 9).
Letendre S.Top Antivir Med. 2011 Nov;19(4):137-42.Gates TM., et al. AIDS 2016, 30:591–600
![Page 28: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/28.jpg)
Robertson KR., et al. AIDS 2016, 30:2315–2321
• 262 ART-naive, chemokine coreceptor 5 tropic HIV, and HIV RNA greater than 1000 copies/ml participants were randomized.
• N= 119 DRV/r + ETV + MVC• N= 111 DRV/r + ETV + TDF
Improvement in both arms,But NO difference between them.
![Page 29: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/29.jpg)
Yilmaz A, et al. (2009) PLoS ONE 4(9): e6877
![Page 30: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/30.jpg)
Despite the favorable characteristics of raltegravir for CNS treatment, no evidence was found that intensification reduced either intrathecal immunoactivation or CSF HIV-1 RNA in study subjects
Dahl V., et al. The Journal of Infectious Diseases 2011;204:1936–45
![Page 31: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/31.jpg)
• DTG concentrations in CSF were similar to unbound plasma concentrations and exceeded the in vitro 50% inhibitory concentration for wild-type HIV (0.2 ng/mL), suggesting that DTG achieves therapeutic concentrations in the central nervous system.
• HIV-1 RNA reductions were similar in CSF and plasma
Letendre S., et al. Clinical Infectious Diseases 2014;59(7):1032–7
![Page 32: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/32.jpg)
Change in neuropsychological testing performance (NPZ-4) over 24 weeks by randomized arm.Participants demonstrate improvement with no differences noted by arm.
Valcour VG., et al. PLoS ONE 2015; 10(11): e0142600
![Page 33: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/33.jpg)
![Page 34: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/34.jpg)
• N=167, median nadir CD4 of 436 cells/mm3 ; 4.5 median years on ART, before interruption.
Robertson KR., et al. Neurology 2010;74:1260 –1266
• Significant improvements in mean neuropsychological scores of 0.22, 0.39, 0.53, and 0.74 were found at weeks 24, 48, 72, and 96 (p< 0.001).
![Page 35: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/35.jpg)
Condition First line choice Not recommended
HIV associatedNeurocognitive and psychiatric disorders
Insufficient evidence. Integrase INSTI, MVC, DRV/r, ABC/3TC mightbe more effective
- EFV, - RPV?- NVP?
![Page 36: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/36.jpg)
CROI, Seattle, February 13-16, 2017. Abstract 352LB.
• HIV+ had abnormalities in measures of brain structure and function at baseline.
• There was no difference in the dynamics of these measures over time between PLWHIV and HIV-negative controls.
• Cognitive performance did not decline over two years.
• No evidence for accelerated brain ageing during continued suppressed viraemia on cART
![Page 37: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/37.jpg)
• HAND remains frequent despite cART• More prevalent and severe in aging individuals.• Periodic screening with basic tools is mandatory• Asymptomatic impairment may not be that
asymptomatic• Comorbid illnesses are important contributors to
impairment, particularly in older age• cART improves but does not revert HAND• Best practice for cART High CPE score, low CNS
toxicity, however, evidence is lacking.
![Page 38: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/38.jpg)
![Page 39: Internal Medicine, Infectious Diseasesregist2.virology-education.com/2017/andWorkshop/20_Martinez.pdf · The Journal of Infectious Diseases 2011;204:1936–45 • DTG concentrations](https://reader031.fdocuments.us/reader031/viewer/2022011823/5ed7ccef8e533201dc4ad6d9/html5/thumbnails/39.jpg)
G r a c i a s p o r s u a t e n c i ó n . . .